Transgene Biotek Limited has officially communicated to the Bombay Stock Exchange (BSE) that it does not meet the criteria to be classified as a "Large Corporate" under the Securities and Exchange Board of India (SEBI) regulations. The confirmation was made through a formal letter dated April 13, 2026, signed by the company's Chairman and Managing Director, Dr K Koteswara RAO.

Regulatory Compliance Confirmation

The company's declaration specifically references SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which pertains to fund raising by issuance of debt securities by large entities. Additionally, the communication cites BSE Circular No. LIST/COM/05/2019-20 dated April 11, 2019, which provides further guidance on the implementation of these regulations.

Large Corporate Classification Criteria

According to the company's statement, Transgene Biotek Limited does not fulfill the criteria specified in Para 2.2 of the aforementioned SEBI circular. This means the biotechnology company remains outside the regulatory framework that governs large corporate entities in terms of debt securities issuance and related compliance requirements.

Corporate Governance and Transparency

The proactive communication to the stock exchange demonstrates the company's commitment to maintaining transparency with regulatory authorities and ensuring proper classification under applicable securities regulations. This formal confirmation helps establish clear regulatory positioning for the company and its stakeholders.

The letter was submitted to the General Manager of the Bombay Stock Exchange Limited's Listing Compliance Department, ensuring that the exchange has updated records regarding the company's regulatory status for future reference and compliance monitoring.

Transgene biotek Limited has formally notified the Bombay Stock Exchange (BSE) regarding the non-applicability of SEBI Regulation 32(1) compliance requirements for the quarter ended March 31, 2026. The communication, dated April 13, 2026, was addressed to the General Manager of BSE's Listing Compliance Department.

Regulatory Compliance Notice

The company's intimation relates to SEBI Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed entities to submit statements of deviation or variation for proceeds from various capital raising activities. This requirement is based on SEBI circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, and subsequent amendments.

Non-Applicability Confirmation

Transgene Biotek Limited confirmed that during the reporting quarter ended March 31, 2026, the company did not undertake any of the following activities:

• Public issues
• Rights issues
• Preferential issues
• Qualified Institutions Placement (QIP)

Due to the absence of these capital raising activities, the Statement of Deviation or Variation requirements under Regulation 32(1) are not applicable to the company for Q4FY26.

Filing Challenges

The company also highlighted a technical issue with the regulatory filing system, noting that they were unable to file under XBRL mode as the form does not allow NIL entries. This technical constraint necessitated the formal intimation to BSE through alternative communication channels.

Management Authorization

The intimation was formally signed and submitted by Dr. K Koteswara Rao, Chairman & Managing Director of Transgene Biotek Limited, ensuring proper management authorization for the regulatory communication.